Cingulate Shares Are Trading By More Than 200% Friday: What You Need To Know
Portfolio Pulse from Vaishali Prayag
Cingulate Inc. (NASDAQ:CING) shares surged by 239% after the company was granted a European patent for its ADHD treatment, CTx-1301. This patent covers up to 30 European territories, including the UK. Cingulate is also preparing to file a New Drug Application with the U.S. FDA.
August 16, 2024 | 6:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cingulate Inc. shares surged by 239% after the company was granted a European patent for its ADHD treatment, CTx-1301. This patent covers up to 30 European territories, including the UK. Cingulate is also preparing to file a New Drug Application with the U.S. FDA.
The European patent significantly expands Cingulate's market potential for CTx-1301, boosting investor confidence. The upcoming NDA filing with the U.S. FDA further adds to the positive outlook, driving the stock price up by 239%.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100